As of October 2009, 11 studies were planned or recruiting patients, including studies on the clinical effects of exenatide or GLP-1 on outcomes of patients in the cardiac intensive care unit, post-PCI patients, post-CABG patients, and patients with HF (Table 4). The gene discussed is GCG; the disease is hydrops fetalis.